Overexpression of cytoplasmic dynamin 2 is associated with worse outcomes in patients with clear cell renal cell carcinoma.

IF 1.8 4区医学 Q3 ONCOLOGY

Cancer Biomarkers Pub Date : 2022-01-01 DOI:10.3233/CBM-210514

Sadegh Safaei, Roya Sajed, Leili Saeednejad Zanjani, Mandana Rahimi, Fahimeh Fattahi, Golnaz Ensieh Kazemi-Sefat, Mahdieh Razmi, Shima Dorafshan, Leila Eini, Zahra Madjd, Roya Ghods

{"title":"Overexpression of cytoplasmic dynamin 2 is associated with worse outcomes in patients with clear cell renal cell carcinoma.","authors":"Sadegh Safaei, Roya Sajed, Leili Saeednejad Zanjani, Mandana Rahimi, Fahimeh Fattahi, Golnaz Ensieh Kazemi-Sefat, Mahdieh Razmi, Shima Dorafshan, Leila Eini, Zahra Madjd, Roya Ghods","doi":"10.3233/CBM-210514","DOIUrl":null,"url":null,"abstract":"Background: Dynamin 2 (DNM2) involved in tumor progression in various malignancies.Objective: For the first time, we evaluated DNM2 expression pattern, its association with clinicopathological characteristics and survival outcomes in RCC subtypes.Methods: We evaluated the DNM2 expression pattern in RCC tissues as well as adjacent normal tissue using immunohistochemistry on tissue microarray (TMA) slides.Results: Our findings revealed increased DNM2 expression in RCC samples rather than in adjacent normal tissues. The results indicated that there was a statistically significant difference between cytoplasmic expression of DNM2 among subtypes of RCC in terms of intensity of staining, percentage of positive tumor cells, and H-score (P= 0.024, 0.049, and 0.009, respectively). The analysis revealed that increased cytoplasmic expression of DNM2 in ccRCC is associated with worse OS (log rank: P= 0.045), DSS (P= 0.049), and PFS (P= 0.041). Furthermore, cytoplasmic expression of DNM2 was found as an independent prognostic factor affecting DSS and PFS in multivariate analysis.Conclusions: Our results indicated that DNM2 cytoplasmic expression is associated with tumor aggressiveness and poor outcomes. DNM2 could serve as a promising prognostic biomarker and therapeutic target in patients with ccRCC.","PeriodicalId":56320,"journal":{"name":"Cancer Biomarkers","volume":"56 1","pages":"27-45"},"PeriodicalIF":1.8000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12364225/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biomarkers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3233/CBM-210514","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Dynamin 2 (DNM2) involved in tumor progression in various malignancies.

Objective: For the first time, we evaluated DNM2 expression pattern, its association with clinicopathological characteristics and survival outcomes in RCC subtypes.

Methods: We evaluated the DNM2 expression pattern in RCC tissues as well as adjacent normal tissue using immunohistochemistry on tissue microarray (TMA) slides.

Results: Our findings revealed increased DNM2 expression in RCC samples rather than in adjacent normal tissues. The results indicated that there was a statistically significant difference between cytoplasmic expression of DNM2 among subtypes of RCC in terms of intensity of staining, percentage of positive tumor cells, and H-score (P= 0.024, 0.049, and 0.009, respectively). The analysis revealed that increased cytoplasmic expression of DNM2 in ccRCC is associated with worse OS (log rank: P= 0.045), DSS (P= 0.049), and PFS (P= 0.041). Furthermore, cytoplasmic expression of DNM2 was found as an independent prognostic factor affecting DSS and PFS in multivariate analysis.

Conclusions: Our results indicated that DNM2 cytoplasmic expression is associated with tumor aggressiveness and poor outcomes. DNM2 could serve as a promising prognostic biomarker and therapeutic target in patients with ccRCC.

查看原文本刊更多论文

细胞质动力蛋白2的过度表达与透明细胞肾细胞癌患者较差的预后相关。

背景：动力蛋白2 （DNM2）参与多种恶性肿瘤的进展。目的：我们首次评估了DNM2表达模式及其与RCC亚型临床病理特征和生存结局的关系。方法：采用组织微阵列（TMA）载玻片免疫组化技术，对RCC组织及邻近正常组织中DNM2的表达模式进行了评价。结果：我们的研究结果显示，在RCC样本中，DNM2表达增加，而不是在邻近的正常组织中。结果显示，不同亚型RCC细胞质中DNM2的表达在染色强度、肿瘤阳性细胞百分比、h -评分方面差异均有统计学意义（P分别为0.024、0.049、0.009）。分析显示，ccRCC细胞质中DNM2表达增加与较差的OS （log rank: P= 0.045）、DSS （P= 0.049）和PFS （P= 0.041）相关。此外，在多因素分析中发现细胞质中DNM2的表达是影响DSS和PFS的独立预后因素。结论：我们的研究结果表明，DNM2细胞质表达与肿瘤侵袭性和不良预后有关。DNM2可作为ccRCC患者预后的生物标志物和治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Biomarkers ONCOLOGY-

CiteScore

5.20

自引率

3.20%

发文量

195

审稿时长

3 months

期刊介绍： Concentrating on molecular biomarkers in cancer research, Cancer Biomarkers publishes original research findings (and reviews solicited by the editor) on the subject of the identification of markers associated with the disease processes whether or not they are an integral part of the pathological lesion. The disease markers may include, but are not limited to, genomic, epigenomic, proteomics, cellular and morphologic, and genetic factors predisposing to the disease or indicating the occurrence of the disease. Manuscripts on these factors or biomarkers, either in altered forms, abnormal concentrations or with abnormal tissue distribution leading to disease causation will be accepted.